...
首页> 外文期刊>Journal of Immunological Methods >Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX (R) and Quanterix SiMoA methodologies
【24h】

Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX (R) and Quanterix SiMoA methodologies

机译:使用超声MSD S-Plex(R)和Quanterix SimoA方法的人血清和血浆中IL-21测量

获取原文
获取原文并翻译 | 示例
           

摘要

IL-21 is a pleiotropic cytokine that plays a key role in modulating inflammatory responses, including the promotion of autoimmune diseases. Several groups have quantitated circulating levels of IL-21 in plasma and serum samples using various commercial ELISAs. We determined, however, that the most commonly used commercial assays in published literature were not specific or sensitive enough to detect levels of IL-21 in heparin plasma or serum from healthy human individuals. This finding prompted an effort to develop more specific and sensitive methods to quantitate IL-21 in complex biological matrices using proprietary anti-IL-21 antibodies with the Quanterix SiMoA platform and the Meso Scale Discovery (MSD) 5-PLEX (R) format. Assays developed on both technology platforms were characterized in heparin plasma and serum using spike recoveries across a range of concentrations. Each method was able to detect sub-pg/mL levels of IL-21 (predicted Limit of Detection [LOD] of approximately 1.0 fg/mL for both the Quanterix SiMoA and MSD 5-PLEX (R) platforms) which is 200-500 times lower than current commercial assays. Additionally we demonstrated that rheumatoid factor did not interfere with measuring IL-21 in the Quanterix SiMoA assay. Results obtained with the two new ultrasensitive assays showed a strong correlation (r = 0.9428; p < .0001). Additionally, IL-21 levels were significantly increased in samples from patients with Systemic Lupus Erythematosus (mean +/- SD: n = 14, 202.64 +/- 111.47 fg/mL, p = .0001 for Quanterix SiMoA and 275.4 +/- 174.66 fg/mL p = .0001 for MSD 5-PLEX (R)) as well as in samples from patients with Sjogren's Syndrome (mean +/- SD: n = 11, 122.18 +/- 84.50 fg/mL, p = .0029 for Quanterix SiMoA and 183.64 +/- 153.00 fg/mL, p = .0082 for MSD 5-PLEX (R)) when compared to healthy donors (mean +/- SD: n = 11, 38.1 +/- 27.8 fg/mL for Quanterix SiMoA and 58.1 +/- 30.7 fg/mL for MSD S-PLEX (R)). These ultrasensitive assays, for the first time, allow for the accurate quantization of human IL-21 in heparin plasma and serum. In addition, these experiments also provide a direct comparison of the MSD 5-PLEX (R) format and Quanterix SiMoA platform technologies, which may have broader implications to future application of these methods to evaluate low abundance proteins in complex biological matrices.
机译:IL-21是一种在调节炎症反应方面发挥关键作用的肺炎细胞因子,包括促进自身免疫性疾病。几组使用各种商业ELISA在血浆和血清样品中具有量化IL-21的循环水平。然而,我们确定出版文献中最常用的商业测定法没有足够的特异性或敏感,以检测肝素血浆或来自健康人体的血清中的IL-21水平。这一发现促使努力开发更具体和敏感的方法来定量IL-21在复杂的生物学矩阵中使用专有的抗IL-21抗体,与Quanterix SimoA平台和Meso Scale Discovery(MSD)5-Plex(R)格式。在两种技术平台上开发的测定在肝素血浆和血清中,使用尖峰复苏跨越一系列浓度。每种方法能够检测Quanterix SimoA和MSD 5-Plex(R)平台的亚峰/ mL水平的IL-21(预测的检测极限为约1.0fg / ml),这是200-500时间低于当前商业测定。此外,我们证明了类风湿因子在Quanterix SimoA测定中没有干扰测量IL-21。用两种新的超敏测定获得的结果表明强相关(r = 0.9428; p <.0001)。另外,Systemic Lupus红斑患者的样品中IL-21水平显着增加(平均+/-SD:n = 14,202.64 +/-11.47 fg / ml,p = .0001,用于Quanterix SimoA和275.4 +/- 174.66用于MSD 5-Plex(R)的FG / ml P = .0001)以及来自Sjogren综合征患者的样品(平均+/- SD:n = 11,122.18 +/- 84.50 fg / ml,p = .0029与健康供体相比,对于Quanterix SimoA和183.64 +/-153.00 fg / ml,p = .0082)用于MSD 5-Plex(R)的P = .0082(平均+/- SD:n = 11,38.1 +/- 27.8 fg / ml对于MSD S-Plex(R)的Quanterix SimoA和58.1 +/- 30.7 FG / ml)。首次进行这些超声测定允许在肝素等离子体和血清中准确地量化人IL-21。此外,这些实验还提供了MSD 5-Plex(R)格式和Quanterix SimoA平台技术的直接比较,这可能对这些方法的未来应用来评估复杂生物学基质中的低丰度蛋白质来说,这可能具有更广泛的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号